172 results
Page 6 of 9
8-K
EX-99.1
wssz t8gp56h
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
soir34
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-99.1
5ry6td2ij hf6c
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
zh5rqb3e
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-10.1
idy465l1cqlsgn
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
vay9y6675gwj
1 Aug 19
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
7:23am
8-K
EX-99.1
u6pfwq4tiuq ek1s
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-99.1
tjy8kpvry0kww7
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
x5cvvvn0
22 Jul 19
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
8:08am
8-K
EX-99.1
j8zgkl u7ed
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
keyminze5n7 zavu9y
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.1
dldt5 ap0
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
nfjb7tv 651ts0bpyqu
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
afwhxnrxnmohzte
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
uuebbf ns7
6 May 19
Adaptimmune Reports First Quarter 2019 Financial Results
7:38am
8-K
EX-99.1
q31kszx6o
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am